Introduction {#Sec1}
============

Transcatheter aortic valve replacement (TAVR) has become a widely accepted treatment option for patients with severe aortic stenosis (AS) who are considered intermediate- and high-risk surgical candidates. However, TAVR is not without potential complications; one of the most common being new onset of intraventricular conduction delay \[i.e., left bundle branch block (LBBB) or right bundle branch block (RBBB)\] \[[@CR1]\]. The clinical impact of these intraventricular conduction delays is controversial. Of note, a 2016 meta-analysis demonstrated that new-onset LBBB after TAVR was associated with increased mortality and permanent pacemaker (PPM) implantation at 1 year \[[@CR2]\]. Baseline RBBB has been associated with poorer clinical outcomes (such as increased mortality) after TAVR \[[@CR3]\], although the impact of new-onset RBBB after TAVR is not well known. The purpose of this study was to test the hypothesis that transapical TAVR would be associated with increased risk of new-onset intraventricular conduction delay (LBBB or RBBB).

Methods {#Sec2}
=======

We performed a retrospective, observational study of consecutive patients undergoing TAVR between January 1, 2012 and February 15, 2018, which was approved by the Florida Hospital Institutional Review Board (IRB) prior to data collection, which conformed with the Helsinki Declaration of 1964, as revised in 2013, concerning human and animal rights. Informed consent was obtained by the patients for being included in the study.

A total of 23 patients with previously identified LBBB/RBBB/PPM, lack of medical, surgical, and/or demographic information, and those who were not between 18 and 90 years old were excluded. The incidence of new LBBB or RBBB, in addition to demographic information, was recorded. All TAVR patients meeting inclusion criteria had telemetry monitoring for at least 24 h following the procedure.

The incidence of new LBBB or RBBB was determined between femoral and apical TAVR patients using the Chi-square test or Fischer\'s exact test of independence. Multivariate analysis was performed to account for confounding variables, which included age, gender, CAD, PAD, hypertension, and diabetes. All tests were two-tailed and a value of 0.05 was selected for statistical significance. No *p* value adjustment was made for multiple tests conducted. Statistical analysis was performed with SAS 9.4 (SAS Institute, Cary, NC, USA).

Results {#Sec3}
=======

A total of 489 TAVR patients were included in the study, with 302 (62%) femoral approach and 187 (38%) apical approach. With respect to demographics, the two groups were well matched, except those undergoing transapical TAVR had a higher incidence of peripheral arterial disease (PAD) and smoking history (Table [1](#Tab1){ref-type="table"}).Table 1Summary demographicsTransfemoralTransapical*p* valueApproach302 (62)187 (38)Age, years, median (range)81 ± 8.9 (46--96)82 ± 8 (41--99)0.12Male171 (57)112 (60)0.48Race/ethnicity0.7Nonhispanic white268 (89)161 (86)Nonhispanic black6 (2)4 (2)Hispanic18 (6)15 (8)Asian3 (1)4 (2)Other7 (2)3 (2)CAD226 (75)152 (81)0.11Hypertension284 (94)175 (94)0.73Pulmonary hypertension42 (14)19 (10)0.22Diabetes111 (37)62 (33)0.39BMI,*n*, mean28.3 ± 9.828.5 ± 15.8nsObesity92 (31)54 (29)0.67Chronic liver disease8 (3)3 (2)0.45Non-aortic valve disease220 (73)145 (77)0.27Bicuspid aortic valve9 (3)5 (3)0.77Congenital heart disease16 (5)0 (0)0.0013\*CVA39 (13)23 (12)0.83PAD67 (22)83 (44)\< 0.0001\*Smoking (current or prior)151 (51)114 (62)0.0162\*Data are numbers of participants, with percentages in parentheses*BMI* body mass index, *CAD* coronary artery disease, *CVA* stroke, *PAD* peripheral artery disease\*Statistically significant

Pre-procedurally, the two groups were similar, except those undergoing transfemoral TAVR more often had prior PPM and moderate/severe left ventricular outflow tract (LVOT) calcification (Table [2](#Tab2){ref-type="table"}). Intra-procedurally, those undergoing transapical TAVR more frequently demonstrated malposition of the prosthesis (including low implantation depth) or required subsequent TAV-in-TAV deployment (Table [3](#Tab3){ref-type="table"}).Table 2Preprocedural characteristicsTransfemoralTransapical*p* valuePermanent pacemaker19 (6)3 (2)0.014\*Prior IVCD57 (19)30 (16)0.43RBBB37 (12)22 (7)0.87LBBB20 (11)8 (4)0.28Degree of AV calcification0.3 Minimal5 (2)1 (1) Mild26 (9)10 (6) Moderate110 (39)59 (35) Severe143 (50)97 (58) Moderate or severe LVOT calcification22 (8)3 (2)0.0001\* Tortuous iliac arteries116 (41)54 (32)0.28Data are numbers of participants, with percentages in parentheses*IVCD* intraventricular conduction delay, *RBBB* right bundle branch block, *LBBB* left bundle branch block, *AV* aortic valve, *LVOT* left ventricular outflow tract\*Statistical significanceTable 3Intraprocedural outcomesTransfemoralTransapical*p* valueMalposition of bioprosthesis including low implantation depth\*\*13 (4)18 (10)0.02\*Unplanned use of cardiopulmonary bypass1 (0.5)1 (0.3)0.73Conversion to open surgery3 (1)1 (0.5)0.58TAV-in-TAV deployment13 (4)18 (10)0.02\*Aortic rupture1 (0.3)0 (0)0.62Aortic dissection0 (0)0 (0)Ventricular septal perforation0 (0)2 (1)0.15Acute severe aortic regurgitation0 (0)1 (0.3)0.62Mitral valve damage0 (0)0 (0)Guidewire related trauma4 (1)1 (0.5)0.65Major bleeding8 (3)9 (5)0.2Mortality0 (0)1 (0.5)0.38Data are numbers of participants, with percentages in parentheses*TAV* transcatheter aortic valve\*Statistical significance\*\*Depth of intraventricular end of bioprosthesis \> 6 mm below annulus is considered low

In univariate analysis, the apical approach (when compared to the femoral approach) was associated with a higher incidence of both new onset LBBB (12.79 vs. 3.40%, *p* = 0.00007) and RBBB (5.49 vs. 1.5%, *p* = 0.01) (Fig. [1](#Fig1){ref-type="fig"}). After controlling for potential confounding variables, the apical approach continued to be associated with a higher incidence of both new onset LBBB (*p* = 0.001) and RBBB (*p* = 0.01) (Table [4](#Tab4){ref-type="table"}). There was also a trend towards an association between diabetes and new-onset LBBB (*p* = 0.0513) in transapical TAVR patients.Fig. 1The apical approach (when compared to the femoral approach) was associated with a higher incidence of both new onset LBBB and RBBBTable 4Logistic regression analysesOdds ratio*p* valueLBBB^a^3.85 (1.72, 9.09)0.001RBBB^a^7.69 (1.56, 33.3)0.0115Periprocedural MI (≤ 72 h)3.85 (1.43, 10)0.008Prosthesis malposition2.78 (0.9, 8.3)0.08TAV-in-TAV deployment2.44 (1.15, 5.26)0.02Death from unknown causes (12-month follow-up)7.69 (0.91, 100)0.06Death from non-cardiac causes (12-month follow-up)7.14 (1.51, 33.33)0.01Data are odds ratios with 95% confidence intervals in parenthesesLogistic regression models were fit for TAVR approach (transfemoral vs. transapical), adjusting for age, gender, CAD, PAD, hypertension, and diabetes; limited to examinations with nonmissing covariates*MI* myocardial infarction, *TAV* transcatheter aortic valve^a^LBBB and RBBB subgroups analyzed after excluding patients with history of bundle branch block prior to TAVR

In subgroup analysis, LBBB/RBBB occurring as a result of transapical TAVR was associated with more frequent hospitalizations \> 30 days after TAVR, compared to transfemoral TAVR (Table [5](#Tab5){ref-type="table"}).Table 5Outcomes by type of IVCD\*TransfemoralTransapical*p* valueNew RBBB (*n *= 14) Patients, *n* (after excluding prior RBBB)265165 Permanent pacemaker0 (0)2 (1)0.15 Cardiac resynchronization treatment (CRT)0 (0)0 (0) All-cause rehospitalization \< 30 days after TAVR1 (0.4)2 (1)0.3 Rehospitalization for TAVR complication \< 30 days after TAVR1 (0.4)2 (1)0.3 All-cause hospitalization ≥ 30 days after TAVR0 (0)6 (4)0.003\*\* Hospitalization for MACE ≥ 30 days after TAVR0 (0)4 (2)0.02\*\* Death \< 30 days after TAVR1 (0.4)^a^1 (0.6)^b^0.7 Death ≥ 30 days to  \< 1 year after TAVR0 (0)1 (0.6)^c^0.38New LBBB (*n* = 32) Patients, *n* (after excluding prior LBBB)282179 Permanent pacemaker3 (1)1 (0.5)0.57 Cardiac resynchronization treatment (CRT)0 (0)0 (0) All-cause rehospitalization \< 30 days after TAVR2 (0.7)1 (0.5)0.84 Rehospitalization for TAVR complication \< 30 days after TAVR1 (0.3)1 (0.5)0.74 All-cause hospitalization ≥ 30 days after TAVR4 (1)10 (6)0.01\*\* Cardiac hospitalization ≥ 30 days after TAVR4 (1)7 (4)0.09 Death \< 30 days after TAVR0 (0)0 (0) Death ≥ 30 days to  \< 1 year after TAVR0 (0)1 (0.5)^d^0.39*IVCD* intraventricular conduction delay, *MACE* major adverse cardiovascular event (admission for heart failure, ischemic cardiovascular events, cardiac death, stroke)\*Data are numbers of participants, with percentages in parentheses\*\*Statistically significant^a^Ventricular fibrillation with cardiac arrest during TAVR^b^Heart failure^c^Heart failure^d^Uknown cause

Other post-procedural complications noted more frequently among patients undergoing transapical TAVR include arrhythmias including atrial fibrillation, peri-procedural myocardial infarction (within 72 h), mortality from unknown cause, and mortality from non-cardiac cause (Table [6](#Tab6){ref-type="table"}).Table 6Postprocedural outcomes (within 30 days unless otherwise indicated)TransfemoralTransapical*p* valueConduction disturbances/arrhythmias136 (45)117 (63)0.0002\*RBBB4 (1.5)10 (5.5)0.01\*LBBB9 (3)23 (13)0.00007\*Paravalvular leak (≤ 72 h)70 (23)50 (27)0.38CVA/TIA3 (1)3 (2)0.68Periprocedural MI (≤ 72 h)6 (2)13 (7)0.006\*Myocardial infarction (\> 72 h)2 (0.7)0 (0)0.531-year mortality due to cardiac cause2 (0.7)2 (1)0.631-year mortality due to non-cardiac cause2 (0.7)8 (4)0.008\*1-year mortality due to unknown cause1 (0.3)5 (3)0.02\*Valve-related death0 (0)1 (0.5)0.38Valve thrombosis0 (0)1 (0.5)0.38Acute kidney injury13 (4)13 (7)0.2Bleeding12 (4)13 (7)0.15Endocarditis0 (0)0 (0)Data are numbers of participants, with percentages in parentheses*RBBB* right bundle branch block, *LBBB* left bundle branch block, *CVA/TIA* cerebrovascular accident/transient ischemic attack\*Statistically significant

Discussion {#Sec4}
==========

We found an increased incidence of new-onset BBB in patients undergoing transapical TAVR compared with transfemoral TAVR. Our findings correlate well with those of other TAVR studies \[[@CR4]--[@CR6]\]. The incidence of new-onset LBBB has been more exhaustively analyzed than new-onset RBBB, presumably due to more concerning clinical implications of new-onset LBBB. Published incidence rates of LBBB range from 4 to 65% with first-generation valves and 18--65% with balloon-expandable valves \[[@CR1]\].

Other clinical risk factors that predict new-onset LBBB after TAVR include female gender, previous coronary artery bypass graft (CABG), pre-procedural QRS prolongation, diabetes mellitus, and prosthesis implantation depth within the LVOT, which is the most consistently reported predictor of intraventricular conduction delays \[[@CR1]\]. We found an increased percentage of transapical TAVR patients in our study with low implantation depth, which may help to explain the increased risk of new-onset BBB in this group. Correspondingly, the transapical group was also at increased risk for needing TAV-in-TAV deployment to correct prosthesis malposition.

Our study also demonstrated a trend towards diabetes as an independent risk factor for new-onset LBBB in transapical TAVR patients. This is particularly concerning, as patients with LBBB and diabetes demonstrate more severe left ventricular systolic dysfunction than those with LBBB but without diabetes \[[@CR7]\].

Overall, intra-procedural and post-procedural morbidity and mortality were also increased in the transapical group. This included increased risk for arrhythmias, peri-procedural MI, readmission, and all-cause mortality. We also witnessed a trend towards increased risk of acute kidney injury and significant post-procedural hemorrhage in the transapical group. These findings correspond with a recent publication by Stamou et al. who reported increased risk of blood transfusions, readmission, postoperative stroke, and atrial fibrillation in patients undergoing alternative access (non-femoral) TAVR \[[@CR4]\]. Others have also noticed a trend towards improved 1-year survival rates in the transfemoral TAVR patients relative to the transapical approach \[[@CR5]\].

Study limitations: this study was nonrandomized, with results that may be influenced by unmeasured confounders. The small number of certain outcomes, such as mortality, precludes a more detailed statistical analysis to evaluate for underlying confounding variables. This study was not designed to specifically evaluate mortality in transfemoral vs. transapical TAVR patients according to VARC-2 consensus guidelines \[[@CR6]\] and we encourage future investigators to add to the body of literature in this regard. Data regarding specific valve type were not recorded. Also, data regarding the use of various atrioventricular node-blocking medications and electrocardiographic findings in our patients was not available.

Conclusions {#Sec5}
===========

Relative to transfemoral TAVR, patients undergoing transapical TAVR are at increased risk for new-onset bundle branch block, peri-procedural myocardial infarction, rehospitalization, TAV-in-TAV deployment, and all-cause mortality at 1 year. Interventional cardiologists and cardiothoracic surgeons alike should take these findings into consideration when choosing which approach is most suitable for patients undergoing TAVR for severe aortic stenosis.

**Enhanced digital features**

To view enhanced digital features for this article go to 10.6084/m9.figshare.8094509.

Funding {#FPar1}
=======

No funding or sponsorship was received for this study or publication of this article. The article processing charges were funded by the authors.

Authorship {#FPar2}
==========

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures {#FPar3}
===========

Ali M. Agha, Jeremy R. Burt, Danielle Beetler, Tri Tran, Ryan Parente, William Sensakovic, Yuan Du, and Usman Siddiqui have nothing to disclose.

Compliance with Ethics Guidelines {#FPar4}
=================================

We received the approval of the Florida Hospital institutional review board prior to initiating this study, which conformed to the Helsinki Declaration of 1964, as revised in 2013, concerning human and animal rights. Informed consent was obtained by the patients for being included in the study.

Data Availability {#FPar5}
=================

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. We thank the participants of the study.

Open Access {#d29e1833}
===========

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
